GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » YoY EBITDA Growth

IsoPlexis (IsoPlexis) YoY EBITDA Growth : -27.69% (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. IsoPlexis's YoY EBITDA Growth for the quarter that ended in Dec. 2022 was -27.69%.

IsoPlexis's EBITDA per Share for the three months ended in Dec. 2022 was $-0.77.

IsoPlexis YoY EBITDA Growth Historical Data

The historical data trend for IsoPlexis's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis YoY EBITDA Growth Chart

IsoPlexis Annual Data
Trend Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
- -2,985.21 29.16 67.05

IsoPlexis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.18 89.96 93.40 16.10 -27.69

IsoPlexis YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

IsoPlexis's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-2.434--7.387)/ | -7.387 |
=67.05 %

IsoPlexis's YoY EBITDA Growth for the quarter that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (Q: Dec. 2022 )
=(EBITDA per Share (Q: Dec. 2022 )-EBITDA per Share (Q: Dec. 2021 )) / | EBITDA per Share (Q: Dec. 2021 )) |
=(-0.77--0.603)/ | -0.603 |
=-27.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IsoPlexis YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of IsoPlexis's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

IsoPlexis (IsoPlexis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » YoY EBITDA Growth
Comparable Companies
VAPO AZYO LHDX LUCD SONX EYES CTSO LNSR CFMS PAVM ABT MDT SYK EW BSX SZSE:300760 DXCM ZBH STE ALGN
Traded in Other Exchanges
N/A
Address
35 North East Industrial Road, Branford, CT, USA, 06405
Website
https://www.isoplexis.com
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley officer: Chief Financial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay director, officer: Chief Executive Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii officer: SVP, GC & Secretary 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath director C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm director 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers director C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley director 396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho director, 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel officer: Chief Commercial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou officer: Chief Scientific Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar officer: VP, Finance 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc 10 percent owner 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003